Summary: ew research uncovers how tau pathology spreads and damages synapses in progressive supranuclear palsy (PSP). Using ...

FNP-223, previously known as ASN90, is a reversible and substrate-competitive O-GlcNAcase enzyme inhibitor. The oral investigational drug is expected to rapidly increase O-GlcNAcylated tau proteins, ...

In the city of dreams, one family is trapped in a slow, waking nightmare. This isn’t a sudden story of loss; it’s a story of ...

“When she would fall in public, people just assumed she was drunk,” said Glenn. “One time she fell backwards on the steps and ...

Troculeucel, a cryopreserved, autologous enhanced natural killer cell therapy, has demonstrated preliminary clinical benefit without any drug-related adverse events in two Phase I clinical trials in ...

So, let’s talk about faith. I’m no rabbi or scholar, and I’m not trying to write a religious work. But putting my thoughts ...

John Maskill, 89, decided to walk the Cinder Track after losing his wife to Progressive Supranuclear Palsy (PSP) in March.

In a year-long phase II trial, Ambroxol, a widely used cough medicine in Europe, showed target engagement in patients with ...

When progressive supranuclear palsy (PSP), a rare neurodegenerative disorder, started affecting his movement, his wife and ...

Progressive supranuclear palsy (PSP) affects persons in their late 60s to 70s, because of the shrinkage of the upper ...

Amylyx is a high-risk biotech targeting rare diseases with strong cash reserves. Key trials soon may drive a 40% stock upside.

The table below is a review of notable updates that occurred in June 2025 for investigational products in development (not an inclusive list). Click on the status to view our full coverage.